1,000
Participants
Start Date
October 18, 2024
Primary Completion Date
September 3, 2025
Study Completion Date
September 3, 2025
Budesonide-Formoterol treatment
Budesonide 160 μg/formoterol 4.5 μg, 1 inhalation, BID
Research Site, Beijing
Research Site, Beijing
Research Site, Benxi
Research Site, Shanghai
Research Site, Nanjing
Research Site, Heifei
Research Site, Weifang
Research Site, Yantai
Research Site, Heze
Research Site, Shanghai
Research Site, Jiaxing
Research Site, Jinhua
Research Site, Wenzhou
Research Site, Wenzhou
Research Site, Nanchang
Research Site, Fuzhou
Research Site, Quanzhou
Research Site, Chongqing
Research Site, Xiangtan
Research Site, Zhengzhou
Research Site, Nanyang
Research Site, Shangqiu
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Huizhou
Research Site, Shenzhen
Research Site, Liuzhou
Research Site, Guiyang
Research Site, Zunyi
Research Site, Chengdu
Research Site, Chengdu
Research Site, Suzhou
Research Site, Xi'an
Research Site, Dongguan
Research Site, Fenyang
Research Site, Shijiazhuang
Research Site, Taiyuan
Research Site, Taiyuan
Lead Sponsor
AstraZeneca
INDUSTRY